Verition Fund Management LLC Cyma Bay Therapeutics, Inc. Transaction History

Verition Fund Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $6,656 - $12,895	-527 Reduced 4.93%	10,170 $240,000
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $116,169 - $188,481	10,697 New	10,697 $159,000
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $590,010 - $962,279	100,342 New	100,342 $874,000
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $27,176 - $53,562	15,800 New	15,800 $47,000
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $2 Million - $4.36 Million	-601,828 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $848,577 - $2.56 Million	601,828 New	601,828 $2.1 Million
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $373,216 - $1.66 Million	-280,614 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $1.44 Million - $2.02 Million	280,614 New	280,614 $1.44 Million
Q2 2018 Aug 15, 2018	SELL	$10.66 - $14.38 $222,367 - $299,966	-20,860 Closed	0 $0
Q1 2018 May 16, 2018	BUY	$9.0 - $15.16 $187,740 - $316,237	20,860 New	20,860 $271,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.